ReachMD CME

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-application-unlocking-relapsedrefractory-myeloma-with-celmods/36574/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existi...

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/case-application-frontline-insightstackling-newly-diagnosed-myeloma/36573/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to exist...

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/real-world-ready-practical-tips-for-community-oncologists/36572/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therap...

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/safety-first-navigating-celmod-associated-toxicities/36571/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies....

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/mastering-the-sequence-celmods-across-treatment-lines/36570/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies....

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-targeting-matching-celmods-to-the-right-patient-with-myeloma/36569/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to ex...

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/data-dive-clinical-evidence-behind-celmods/36568/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highl...

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/molecular-magic-decoding-the-unique-mechanism-of-celmods/36562/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapi...

CME credits: 1.00 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/why-celmods-matter-in-myeloma/36558/ Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the per...

CME credits: 0.50 Valid until: 21-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/risk-reduction-with-glp-1-ras-in-individuals-with-ascvd-and-t2d-2025-update/36474/ Subcutaneously-administered GLP-1 RAs have demonstrated cardiovascular and renal risk reduction in individuals with type 2 diabetes at high ASCVD risk; they are recommended in the 2025 ADA Standards of Care as part of...

CME credits: 0.25 Valid until: 15-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-acromegaly-care-individualized-diagnosis-and-management-strategies/33027/ Acromegaly, a rare endocrine disorder caused by excessive growth hormone (GH) secretion, has a profound impact on affected individuals and healthcare systems. Patients often experience delays in diagnos...

CME credits: 0.50 Valid until: 05-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/continuity-in-care-strategies-for-managing-growth-hormone-deficiency-through-lifes-stages/35523/ Join Dr. Aristides Maniatis for this Patient-Clinician Connection, a case-based activity that explores the full spectrum of care in Growth Hormone Deficiency. Through real patient and caregiver dialogues...

CME credits: 0.25 Valid until: 01-08-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-optimizing-perioperative-therapy-in-early-stage-nsclc-a-multidisciplinary-approach/34985/ Perioperative immunotherapy has evolved into a novel therapeutic strategy for early-stage, resectable NSCLC, maximizing the efficacy of immunotherapy when the primary tumor is still pre...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines int...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-and-practice-changing-data-in-immunotherapy-strategies-for-melanoma/36330/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melan...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treating melano...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-braf-mutant-stage-iv-melanoma/36328/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical st...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies fo...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into p...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treat...

CME credits: 1.00 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN ® ), focuses on translating oncology clinical practice guidelines into practical strategies for treati...

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/emerging-therapeutic-developments-in-non-targetable-metastatic-nsclc/36153/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate,...

CME credits: 1.25 Valid until: 31-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/met-and-other-emerging-targets-in-metastatic-nsclc/36152/ The rapid pace of therapeutic advances in lung cancer (LC) demands continual learning and adaptation from oncology clinicians. With new agents, indications, and biomarker-driven strategies emerging at an unprecedented rate, staying current is...